Arteriosclerosis, Vol 8, 168-177, Copyright © 1988 by American Heart Association

ARTICLES

Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes

MR Taskinen, T Kuusi, E Helve, EA Nikkila and H Yki-Jarvinen
Second Department of Medicine, University of Helsinki, Finland.

To study the effects of rigorous insulin therapy on serum lipoproteins in patients with noninsulin-dependent diabetes not controlled with oral agents only, we measured serum lipoproteins, apoproteins, lipolytic enzymes, and glucose disposal using an insulin clamp technique before and after 4 weeks of insulin therapy. Lipoproteins were isolated by ultracentrifugation and high density lipoprotein (HDL) subfractions, by rate-zonal density gradient ultracentrifugation. The group included 11 women and eight men (age 58 +/- 1 years and RBW 125 +/- 4%). Body weight, glycosylated hemoglobin, mean diurnal glucose, plasma free insulin, and glucose uptake (M-value) were 75 vs. 76 kg; 11.9 vs. 8.9%; 234 vs. 124 mg/dl; 12 vs. 27 microU/ml; and 5.0 +/- 0.4 vs. 7.1 +/- 0.6 mg/kg/min before and after insulin therapy, respectively. After insulin therapy there was a decrease of very low density lipoprotein (VLDL) triglyceride (-60%, p less than 0.001) but an increase of HDL2 cholesterol (+21%, p less than 0.001); HDL2 phospholipids (+38%, p less than 0.001); HDL2 proteins (+23%, p less than 0.01); and HDL2 mass (127 +/- 11 vs. 158 +/- 12 mg/dl, p less than 0.001). There was a decrease of HDL3 cholesterol (-13%, p less than 0.05); HDL3 phospholipids (-16%, p less than 0.05); HDL3 proteins (-18%, p less than 0.001); and HDL3 mass (179 +/- 6 vs. 146 +/- 6, p less than 0.01). Zonal profiles showed a redistribution of particles from HDL3 to HDL2. Serum apo A-I increased (p less than 0.05), apo A-II remained constant, but apo B decreased (-29%, p less than 0.001). The most marked change during insulin therapy was a 2.3-fold increase in adipose tissue lipoprotein lipase (LPL) activity (p less than 0.001). The changes of VLDL and HDL subfractions were not explained by respective changes of the blood glucose, free insulin, or M-value. The data indicate that intensive insulin therapy induces antiatherogenic changes in serum lipids and lipoproteins and suggest that the induction of LPL by insulin is the major factor responsible for redistribution of HDL particles from HDL3 to HDL2.

This article has been cited by other articles:

				A. Hiukka, M. Stahlman, C. Pettersson, M. Levin, M. Adiels, S. Teneberg, E. S. Leinonen, L. M. Hulten, O. Wiklund, M. Oresic, et al. ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan Diabetes, September 1, 2009; 58(9): 2018 - 2026. [Abstract] [Full Text] [PDF]

				S. Nakanishi, R. Vikstedt, S. Soderlund, M. Lee-Rueckert, A. Hiukka, C. Ehnholm, M. Muilu, J. Metso, J. Naukkarinen, L. Palotie, et al. Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity J. Lipid Res., February 1, 2009; 50(2): 183 - 192. [Abstract] [Full Text] [PDF]

				N. A. West, R. F. Hamman, E. J. Mayer-Davis, R. B. D'Agostino Jr., S. M. Marcovina, A. D. Liese, P. S. Zeitler, S. R. Daniels, and D. Dabelea Cardiovascular Risk Factors Among Youth With and Without Type 2 Diabetes: Differences and possible mechanisms Diabetes Care, January 1, 2009; 32(1): 175 - 180. [Abstract] [Full Text] [PDF]

				J. J. Albers, S. M. Marcovina, G. Imperatore, B. M. Snively, J. Stafford, W. Y. Fujimoto, E. J. Mayer-Davis, D. B. Petitti, C. Pihoker, L. Dolan, et al. Prevalence and Determinants of Elevated Apolipoprotein B and Dense Low-Density Lipoprotein in Youths with Type 1 and Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 735 - 742. [Abstract] [Full Text] [PDF]

				M. Graner, R. W. James, J. Kahri, M. S. Nieminen, M. Syvanne, and M.-R. Taskinen Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2429 - 2435. [Abstract] [Full Text] [PDF]

				J. Rosenstock, D. Sugimoto, P. Strange, J. A. Stewart, E. Soltes-Rak, G. Dailey, and on behalf of the Insulin Glargine 4014 Study Inves Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care, March 1, 2006; 29(3): 554 - 559. [Abstract] [Full Text] [PDF]

				S. Soderlund, A. Soro-Paavonen, C. Ehnholm, M. Jauhiainen, and M.-R. Taskinen Hypertriglyceridemia is associated with pre{beta}-HDL concentrations in subjects with familial low HDL J. Lipid Res., August 1, 2005; 46(8): 1643 - 1651. [Abstract] [Full Text] [PDF]

				H. E. Lilja, E. Suviolahti, A. Soro-Paavonen, T. Hiekkalinna, A. Day, K. Lange, E. Sobel, M.-R. Taskinen, L. Peltonen, M. Perola, et al. Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia J. Lipid Res., October 1, 2004; 45(10): 1876 - 1884. [Abstract] [Full Text] [PDF]

				M.-L. Liu, K. Ylitalo, R. Salonen, J. T. Salonen, and M.-R. Taskinen Circulating Oxidized Low-Density Lipoprotein and Its Association With Carotid Intima-Media Thickness in Asymptomatic Members of Familial Combined Hyperlipidemia Families Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1492 - 1497. [Abstract] [Full Text] [PDF]

				S. Vehkavaara and H. Yki-Jarvinen 3.5 Years of Insulin Therapy With Insulin Glargine Improves In Vivo Endothelial Function in Type 2 Diabetes Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 325 - 330. [Abstract] [Full Text]

				A. Soro, M. Jauhiainen, C. Ehnholm, and M.-R. Taskinen Determinants of low HDL levels in familial combined hyperlipidemia J. Lipid Res., August 1, 2003; 44(8): 1536 - 1544. [Abstract] [Full Text] [PDF]

				M. G. Wulffele, A. Kooy, P. Lehert, D. Bets, J. C. Ogterop, B. Borger van der Burg, A. J.M. Donker, and C. D.A. Stehouwer Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes Diabetes Care, December 1, 2002; 25(12): 2133 - 2140. [Abstract] [Full Text] [PDF]

				R. Bergholm, M. Leirisalo-Repo, S. Vehkavaara, S. Makimattila, M.-R. Taskinen, and H. Yki-Jarvinen Impaired Responsiveness to NO in Newly Diagnosed Patients With Rheumatoid Arthritis Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1637 - 1641. [Abstract] [Full Text] [PDF]

				M.-L. Liu, K. Ylitalo, I. Nuotio, R. Salonen, J. T. Salonen, and M.-R. Taskinen Association Between Carotid Intima-Media Thickness and Low-Density Lipoprotein Size and Susceptibility of Low-Density Lipoprotein to Oxidation in Asymptomatic Members of Familial Combined Hyperlipidemia Families Stroke, May 1, 2002; 33(5): 1255 - 1260. [Abstract] [Full Text] [PDF]

				J. Vakkilainen, M. Jauhiainen, K. Ylitalo, I. O. Nuotio, J. S. A. Viikari, C. Ehnholm, and M.-R. Taskinen LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins J. Lipid Res., April 1, 2002; 43(4): 598 - 603. [Abstract] [Full Text] [PDF]

				K. Ylitalo, P. Pajukanta, S. Meri, R. M. Cantor, N. Mero-Matikainen, J. Vakkilainen, I. Nuotio, and M.-R. Taskinen Serum C3 but Not Plasma Acylation-Stimulating Protein Is Elevated in Finnish Patients With Familial Combined Hyperlipidemia Arterioscler Thromb Vasc Biol, May 1, 2001; 21(5): 838 - 843. [Abstract] [Full Text] [PDF]

				A. A. Rivellese, L. Patti, G. Romano, F. Innelli, L. Di Marino, G. Annuzzi, M. Iavicoli, G. A. Coronel, and G. Riccardi Effect of Insulin and Sulfonylurea Therapy, at the Same Level of Blood Glucose Control, on Low Density Lipoprotein Subfractions in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4188 - 4192. [Abstract] [Full Text]

				J. Vakkilainen, S. Makimattila, A. Seppala-Lindroos, S. Vehkavaara, S. Lahdenpera, P.-H. Groop, M.-R. Taskinen, and H. Yki-Jarvinen Endothelial Dysfunction in Men With Small LDL Particles Circulation, August 15, 2000; 102(7): 716 - 721. [Abstract] [Full Text] [PDF]

				S. Bioletto, A. Golay, R. Munger, B. Kalix, and R. W James Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects1 Am. J. Clinical Nutrition, February 1, 2000; 71(2): 443 - 449. [Abstract] [Full Text] [PDF]

				S. Vehkavaara, S. Makimattila, A. Schlenzka, J. Vakkilainen, J. Westerbacka, and H. Yki-Jarvinen Insulin Therapy Improves Endothelial Function in Type 2 Diabetes Arterioscler Thromb Vasc Biol, February 1, 2000; 20(2): 545 - 550. [Abstract] [Full Text] [PDF]

				Y. Kako, L.-S. Huang, J. Yang, T. Katopodis, R. Ramakrishnan, and I. J. Goldberg Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: effects on lipoproteins and atherosclerosis J. Lipid Res., December 1, 1999; 40(12): 2185 - 2194. [Abstract] [Full Text] [PDF]

				M.-L. Liu, R. Bergholm, S. Makimattila, S. Lahdenpera, M. Valkonen, H. Hilden, H. Yki-Jarvinen, and M.-R. Taskinen A marathon run increases the susceptibility of LDL to oxidation in vitro and modifies plasma antioxidants Am J Physiol Endocrinol Metab, June 1, 1999; 276(6): E1083 - E1091. [Abstract] [Full Text] [PDF]

				O.-P. Pitkanen, P. Nuutila, O. T. Raitakari, K. Porkka, H. Iida, I. Nuotio, T. Ronnemaa, J. Viikari, M.-R. Taskinen, C. Ehnholm, et al. Coronary Flow Reserve in Young Men With Familial Combined Hyperlipidemia Circulation, April 6, 1999; 99(13): 1678 - 1684. [Abstract] [Full Text] [PDF]

				M. P. Stern The Effect of Glycemic Control on the Incidence of Macrovascular Complications of Type 2 Diabetes Arch Fam Med, March 1, 1998; 7(2): 155 - 162. [Abstract] [Full Text] [PDF]

				B. Gaster and I. B. Hirsch The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes Arch Intern Med, January 26, 1998; 158(2): 134 - 140. [Abstract] [Full Text] [PDF]

				C. Abraira, J. Colwell, F. Nuttall, C. T. Sawin, W. Henderson, J. P. Comstock, N. V. Emanuele, S. R. Levin, I. Pacold, and H. S. Lee Cardiovascular Events and Correlates in the Veterans Affairs Diabetes Feasibility Trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes Arch Intern Med, January 27, 1997; 157(2): 181 - 188. [Abstract] [PDF]

				M. Syvanne, J. Kahri, K. S. Virtanen, and M.-R. Taskinen HDLs Containing Apolipoproteins A-I and A-II (LpA-I:A-II) as Markers of Coronary Artery Disease in Men With Non–Insulin- Dependent Diabetes Mellitus Circulation, August 1, 1995; 92(3): 364 - 370. [Abstract] [Full Text]